EGFR and non-small cell lung carcinoma: In a series of LUX lung clinical trials, afatinib, another second‐generation EGFR TKI, demonstrated clinical activity and survival benefit in EGFR‐mutated NSCLC patients with BMs compared to chemotherapy or first‐generation EGFR TKI.7, 8, 9